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BACKGROUND: Hepatitis B virus (HBV) DNA and
alanine aminotransferase (ALT) levels predict future
complications in chronic hepatitis B (CHB) patients.
To determine when to initiate antiviral therapy,
treatment guidelines recommend monitoring of HBV
DNA and ALT levels at least annually. This study
aimed to assess adherence to treatment guideline-
recommended monitoring of CHB patients not receiv-
ing antiviral treatment and to identify predictors of
laboratory monitoring and subsequent initiation of
antiviral therapy.
METHODS: This retrospective cohort study used data
from a large US health care claims database over a
5-year period (January 1, 2003 to December 31, 2007).
The study population included patients 18–65 years of
age with at least two paid medical claims with an ICD-
9 code for CHB, at least one positive hepatitis B
surface antigen test, and at least 12 months of
continuous health plan enrollment after initial diag-
nosis. Descriptive statistics assessed the proportion of
patients with claims for ALT and/or HBV DNA moni-
toring. Multivariate logistic regression models were
used to determine predictors of monitoring and sub-
sequent antiviral therapy.
RESULTS: The study included 1,168 CHB patients,
with a mean follow-up of 728 days (median=696 days).
The proportion monitored at least every 12 months
was 53.3% for ALT, 39.0% for HBV DNA, and 35.1% for
both. Significant predictors of monitoring were a
higher Deyo-Charlson Comorbidity Index (DCCI) score
for ALT (OR 1.90, p<0.001), male gender for HBV DNA
(OR 1.49, p<0.01), and a higher DCCI score (OR 1.10,
p<0.05) and male gender (1.46, p<0.01) for both.
Significant predictors of subsequent initiation of anti-
viral treatment were HBV DNA monitoring (OR 2.08,
p<0.001), a higher DCCI score (OR 1.24, p<0.001),
and male gender (OR 1.53, p<0.01).
CONCLUSIONS: Laboratory monitoring of CHB
patients not receiving antiviral treatment is below
guideline recommendations, suggesting that initiation
of antiviral therapy may also be delayed, leaving
patients at risk for disease progression.
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INTRODUCTION
An estimated 400 million people are believed to be chronically
infected with hepatitis B virus (HBV) worldwide. Over 1 million
US residents have chronic hepatitis B (CHB) infection, with an
estimated prevalence of 0.3%–0.5%
1,2. In spite of the availabil-
ity of an effective vaccine, the number of US residents with
CHB infection remains high, primarily due to the slow
progression of CHB and the influx of immigrants from
countries with a high prevalence of chronic infection
2.
Approximately 15%–40% of untreated CHB patients will
develop serious hepatic sequelae during their lifetime, includ-
ing cirrhosis, hepatic decompensation, and hepatocellular
carcinoma (HCC)
1,3–5. CHB is currently estimated to contrib-
ute to between 2,000 and 4,000 deaths annually in the US
2.A s
a major cause of cirrhosis and HCC, CHB is a substantial
public health burden, not only in terms of human suffering,
but also in terms of social and economic costs, with over $1
billion spent each year on hepatitis B-related hospitalizations
in the US
2.
A recent report from the Institute of Medicine (IOM)
highlighted that HBV infection is a serious health problem in
the USA
6. Thus, it strongly recommended the implementation
of a national strategy for the prevention and control of HBV
infection
6. The American Association for the Study of Liver
Diseases (AASLD) has responded by joining forces with Trust
for America’s Health (TFAH) to implement a plan of action,
including increased knowledge and awareness about chronic
viral hepatitis among health care providers, social service
providers, and the public; improved surveillance for hepatitis B
and hepatitis C;and betterintegrationofviralhepatitis services
7.
The findings of this study emphasize the importance of CHB and
the need for careful screening and monitoring practices.
Evidence suggests that effective antiviral treatment could
slow the progression of CHB
8. Currently approved drugs for the
treatment of CHB include interferons (interferon-α2b and
peginterferon-α2a) and oral nucleoside or nucleotide analogs
(lamivudine, adefovir dipivoxil, entecavir, telbivudine, and teno-
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239fovir disoproxil fumarate)
5,9. The main goal of CHB therapy is
to prevent the progression of liver disease. Although over 1
million US residents have CHB
1,2,i ti sb e l i e v e dt h a to n l ya
small percentage is being actively treated with antiviral
therapy. While there is little published research on the topic,
a US study found that 93% of CHB patients receiving care at
an urban hospital outpatient clinic were not undergoing
antiviral treatment
10, and, in a European study, 84% of CHB
patients who were candidates for antiviral treatment were not
receiving antiviral treatment
11. Prescription drug sales data
indicate that the majority of patients (>60%) currently receiv-
ing antiviral treatment for CHB in the US are commercially
insured
12.
Persistently elevated serum HBV DNA and alanine amino-
transferase (ALT) levels have been found to be the most
important predictors of future complications in CHB patients,
including cirrhosis, hepatic decompensation, HCC, and
death
2,13–19. The decision to treat CHB with antivirals is
primarily based upon the results of two laboratory tests: high
levels of serum HBV DNA, indicative of active viral replication,
and elevated serum ALT levels, indicative of ongoing liver
injury
9,20. While the ALT level is an important criterion for
assessing the requirement for therapy in most treatment guide-
lines
5,21,22, it can be affected by non-HBV-related factors (e.g.,
body mass index, gender, exercise, abnormal lipid and carbo-
hydrate metabolism, and co-morbidities)
23,24.T h e r e f o r e ,A L T
results should not be used as the sole criterion for initiating
treatment and should instead be assessed in conjunction with
HBV DNA levels
23.
Optimal management of CHB requires routine monitor-
ing, even when patients are asymptomatic, in order to
determine the extent of liver disease progression and the
timing of treatment initiation. Two major CHB treatment
guidelines are widely used in the US: AASLD guidelines and
the US Treatment Algorithm
5,23. The AASLD guidelines
currently recommend both serum ALT and serum HBV
DNA monitoring in untreated CHB patients, with treatment
initiated in those with HBV DNA levels of at least 20,000 IU/
ml and ALT more than twice the upper limit of normal
5.
Patients for whom immediate therapy is not routinely
indicated include patients with CHB in the immune-tolerant
phase (high HBV DNA but normal ALT, or minimal activity
on liver biopsy) and patients in the inactive-carrier or low-
replicative phase (low or undetectable HBV DNA and normal
ALT)
2. Similarly, the US Treatment Algorithm currently
recommends monitoring serum ALT and serum HBV DNA
in patients who do not require treatment
23.
W h i l et h e r ea r el i k e l yt ob em u l t i p l eb a r r i e r st oa p p r o p r i a t e
initiation of treatment, one major factor may be that physi-
cians are not appropriately monitoring the laboratory values
necessary to determine the correct point for treatment
initiation. AASLD guidelines recommend monitoring of both
HBV DNA and ALT levels at least annually
5, although the
recommended frequency of laboratory monitoring may be
higher if laboratory results warrant it. In contrast, the US
Treatment Algorithm currently recommends laboratory mon-
itoring every 3–6m o n t h s
23. The intent of this study is to
examine the quality of care of CHB patients by assessing
adherence to AASLD guideline recommendations in routine
laboratory monitoring of CHB patients not currently receiving
antiviral treatment. For this study, we chose the AASLD
guideline recommendations rather than the US Treatment
Algorithm since they are more conservative in terms of
recommended frequency of CHB laboratory monitoring.
OBJECTIVES
The main objective of this study was to assess the level of
adherence to AASLD CHB treatment guideline recommenda-
tions for laboratory monitoring in CHB patients not receiving
antiviral treatment. The study also aimed to identify predictors
of laboratory monitoring and to identify predictors of subse-
quent initiation of antiviral treatment (oral nucleoside/nucle-
otide analogs, or interferon/peginterferon).
METHODS
Data Source
Administrative databases are increasingly being used for
studying the outcomes of medical care
25,26. This retrospective
cohort study used health care claims data from the Ingenix
LabRx dataset over a 5-year period (January 1, 2003 to
December 31, 2007). The Ingenix LabRx database contains
health care claims for over 15 million commercially insured
outpatients and inpatients across the USA (http://www.ispor.
org/DigestOfIntDB/Default.aspx?rcd=393). Each medical
claim contains primary and secondary diagnosis codes, which
are assigned according to the International Classification of
Diseases, ninth revision (ICD-9)
27. The Ingenix LabRx data-
base includes a very large and diverse set of patients across the
country; however, since claims data are administrative data
and not collected for a specific scientific purpose, these data
cannot be assumed to be nationally representative.
Study Population
The study population included any patient 18–65 years of
a g ew h oh a da tl e a s to n ep o s i t i v eh e p a t i t i sBs u r f a c ea n t i g e n
(HBsAg) test and at least 12 months of continuous enroll-
ment after initial diagnosis. In addition, in order to ensure
that no patients with acute hepatitis B were included in the
study, the inclusion criteria stated that patients had to have
at least two paid medical claims (inpatient or outpatient)
with an ICD-9 code for CHB (070.3×), in line with the
AASLD definition of CHB, which includes HBsAg-positivity
for at least 6 months.
Patients were excluded from the study if they had received
a prescription for any antiviral medication (including lami-
vudine, adefovir, telbivudine, entecavir, tenofovir, emtricita-
bine, or interferon/peginterferon) prior to the monitoring
period. Patients who eventually received antiviral medication
during the monitoring period were only included in the study
up to this event.
A diagnosis of HCC was also an exclusion criterion of the
study.
Outcomes of Interest
The primary outcome of interest was frequency of serum
laboratory testing, specifically testing for ALT and HBV DNA.
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laboratory monitoring (i.e., ALT and HBV DNA) and predictors
for subsequent initiation of antiviral therapy.
Explanatory Variables
Demographic data were collected by the health care provider
and reported on the patient’s medical claim. Clinical vari-
ables, defined using ICD-9 coding, were also reported on the
patient’s medical claim. Note that, while laboratory results
for the presence of HBsAg (dichotomous variable) formed
part of the inclusion criteria for defining the analytic
sample, ALT and HBV DNA test results were not assessed
as that would have required taking continuous variables
and turning them into dichotomous variables (taking test
values and classifying patient results as “normal” and
“abnormal”). The Deyo-Charlson Comorbidity Index, a clin-
ical comorbidity index for use with ICD-9 administrative
databases, was included as a variable in the study. The
Deyo-Charlson Comorbidity Index score is calculated based
on the number of comorbidities the patient has and the
severity of those comorbidities; the higher the score, the
greater is the disease burden
28.
Statistical Analysis
Descriptive statistics assessed the characteristics of the
study sample, including age, sex, geographical region, and
Deyo-Charlson Comorbidity Index. Data captured included
the proportion of patients with claims for ALT and/or HBV
D N Al a b o r a t o r yt e s t i n ga ta n yt i m ed u r i n gf o l l o w - u p ,a n d
the proportion with claims for ALT and HBV DNA laboratory
tests at least once during the first 12 months of follow-up
(±60 days; equivalent to patients meeting guideline criteria).
Descriptive statistics compared unadjusted levels of moni-
toring and subsequent treatment in aggregate and by
patient characteristic.
Multivariate logistic regression was used to determine
predictors of monitoring using ALT testing, HBV DNA testing,
and both ALT and HBV DNA testing as dichotomous outcome
variables. Variables examined included age, sex, region, and
Deyo-Charlson Comorbidity Index. Multivariate logistic re-
Any claim for CHB
(n=49,902)
Two claims for CHB
(n=16,120)
At least one HBV HBsAg claim
(n=2,023)
Age 18−65
(n=6,475)
12 months post-diagnosis enrollment
(n=6,846)
At least one HBV HBsAg(+) test
(n=1,168)
Antiviral treatment (n=1,766)
HCC (n=377)
Figure 1. Patient flow. CHB, chronic hepatitis B; HCC, hepatocellular carcinoma; HBV, hepatitis B virus; HBsAg, hepatitis B surface antigen.
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initiation of antiviral therapy using the same variables, as
well as ALT or HBV DNA monitoring as additional predictors.
RESULTS
Study Sample
Of 16,120 patients with two claims with a diagnosis of CHB,
1,168 met the full inclusion criteria (Fig. 1). Table 1 sum-
marizes the characteristics of the study population, which had
a mean age of 40.6 (SD, 10.5) years, was 58.3% male, and had
a mean follow-up time of 728 (SD, 510.9) days (median=
696 days).
Adherence to Guideline-Recommended
Monitoring
The proportion of patients who received monitoring at least
every 12 months was 53.3% for ALT, 39.0% for HBV DNA,
and 35.1% for both ALT and HBV DNA (Table 2). During this
period, the mean number of tests per patient was 1.7 for
ALT (median=1.0) and 1.1 for HBV DNA (median=1.0). The
proportion of patients who received laboratory monitoring at
any time point during follow-up was 93.7% for ALT, 79.6%
for HBV DNA, and 76.4% for both ALT and HBV DNA
(Table 2). During this period, the mean number of tests per
patient was 5.0 for ALT (median=3.0) and 3.4 for HBV DNA
(median=2.0). Approximately 32% of patients were eventu-
ally treated with an antiviral medication during the follow-
up period (n=375; Table 2).
Predictors of Laboratory Monitoring
Table 3 summarizes the unadjusted estimates of outcomes by
predictors of laboratory monitoring for CHB, while Table 4
summarizes results of the logistic regression analyses, includ-
ing predictors of laboratory monitoring. The only significant
Table 1. Sample Demographics
Total sample (N=1,168)
Age, mean (SD) 40.6 (10.6)
Male, n (%) 680 (58.3)
Days follow-up, mean (SD) 728.0 (510.9)
Region, n (%)
Northeast 228 (19.0)
South 730 (60.9)
West 71 (5.9)
Midwest 169 (14.1)
Deyo-Charlson Comorbidity Index
† 0.83
†Deyo-Charlson comorbidity score is directly proportional to disease
burden
Table 2. Monitoring and Treatment Patterns
Total sample (N=1,168)
ALT, n (%)
Any time point 1095 (93.8)
At least q12 months 622 (53.3)
HBV DNA, n (%)
Any time point 930 (79.6)
At least q12 months 455 (39.0)
ALT and HBV DNA, n (%)
Any time point 892 (76.4)
At least q12 months 410 (35.1)
Subsequent antiviral treatment, n (%) 375 (32.1)
ALT, alanine aminotransferase; HBV, hepatitis B virus
Table 3. Unadjusted Estimates of Laboratory Monitoring and
Initiation of Subsequent Antiviral Treatment for Chronic Hepatitis B
According to Patient Variables
Variable ALT
anytime
HBV DNA
anytime
ALT+HBV DNA
anytime
Antiviral
treatment
Mean age, years 40.9 40.7 40.7 42.4
Sex, %
Male 94.3 80.8 77.4 37.8
Female 93.0 78.0 75.0 24.2
Region, %
Northeast 94.0 89.2 87.7 30.2
South 93.7 79.8 75.3 33.2
West 95.1 78.5 78.7 39.2
Midwest 93.2 66.4 64.9 27.1
Deyo-Charlson
Comorbidity Index
†,
mean
0.87 0.83 0.88 1.31
†Deyo-Charlson comorbidity score is directly proportional to disease
burden
ALT, alanine aminotransferase; HBV, hepatitis B virus
Table 4. Predictors of Laboratory Monitoring and Initiation of
Subsequent Antiviral Treatment for Chronic Hepatitis B
Variable ALT
anytime
OR
(95% CI)
HBV DNA
anytime OR
(95% CI)
ALT+HBV
DNA
anytime OR
(95% CI)
Antiviral
treatment OR
(95% CI)
Age 1.01 (0.99,
1.04)
0.99 (0.98,
1.01)
1.00 (1.00,
1.01)
1.00 (0.99,
1.02)
Male 1.61 (0.98,
2.62)
1.49 (1.11,
2.01)**
1.46 (1.10,
1.94)**
1.53 (1.16,
2.01)**
Region (reference=Northeast)
South 0.90 (0.45,
1.79)
0.68 (0.44,
1.06)
0.67 (0.45,
1.02)
1.07 (0.75,
1.53)
West 1.17 (0.35,
3.85)
0.65 (0.33,
1.29)
0.68 (0.35,
1.31)
1.32 (0.72,
2.41)
Midwest 0.93 (0.38,
2.23)
0.29 (0.17,
0.50)***
0.32 (0.19,
0.53)***
0.89 (0.54,
1.47)
Deyo-Charlson
Comorbidity
Index
†
1.90 (1.33,
2.71)***
1.05 (1.00,
1.13)
1.10 (1.01,
1.19)*
1.24 (1.17,
1.33)***
ALT monitored - - - 0.26 (0.14,
0.41)***
HBV DNA
monitored
- - - 2.08 (1.47,
2.93)***
†Deyo-Charlson comorbidity score is directly proportional to disease
burden
*p<0.05; **p<0.01; ***p<0.001. Based on multivariate logistic regression
ALT, alanine aminotransferase; HBV, hepatitis B virus
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Comorbidity Index score (OR 1.90, p<0.001, Table 4). Signif-
icant differences in monitoring of HBV DNA were observed for
gender and region. Males were more likely to be monitored
than females (OR 1.49, p<0.01), while patients in the Midwest
were less likely to be monitored than patients in the Northeast
(OR 0.29, p<0.001, Table 4).
The significant predictors of monitoring for combined ALT
a n dH B VD N Aw e r et h es a m ea st h ep r e d i c t o r sf o rt h e
individual assays, with a higher Deyo-Charlson Comorbidity
Index score (OR 1.10, p<0.05) and male sex (1.46, p<0.01)
both positively associated with dual monitoring (Table 4).
Predictors of Initiation of Antiviral Treatment
Unadjusted estimates of outcomes by predictors of subsequent
antiviral treatment for CHB are summarized in Table 3.
Table 4 summarizes results of the logistic regression analyses,
including predictors of subsequent initiation of antiviral
treatment. Initiation of antiviral treatment was found to be
more likely among those who received HBV DNA monitoring
(OR 2.08, p<0.001), males (OR 1.53, p<0.01), and patients
with higher Deyo-Charlson Comorbidity Index scores
(OR 1.24, p<0.001; Table 4). Conversely, antiviral treatment
initiation was less likely among patients receiving ALT moni-
toring only (OR 0.26, p<0.001; Table 4).
DISCUSSION
The results of this study suggest that rates of guideline-
recommended laboratory monitoring of ALT and HBV DNA in
untreated patients with CHB are low, with high variability
according to the specific test. Only about one-third of patients
received both ALT and HBV DNA tests on an annual basis.
Although ALT assessment is the more frequently applied of the
two tests, only slightly more than half of all patients receive
annual ALT testing. ALT testing also appears to be applied in a
non-specific manner, as the only predictor of monitoring was
comorbidity burden (Table 4). This is probably because ALT
testing may be obtained for reasons other than for monitoring
liver damage caused by HBV, for example, liver damage caused
by disorders of the gall bladder or pancreas, or caused by
drugs or alcohol; thus not everyone with elevated ALT would
have received antiviral treatment.
The study shows that HBV DNA monitoring rates are lower
than rates of ALT monitoring, and HBV DNA monitoring
appears to be more specifically applied than ALT monitoring,
as it is not influenced by comorbidities. This is perhaps
unsurprising as liver function tests represent a relatively quick
and inexpensive way of monitoring the need to treat, so it is
possible that physicians are using these tests as an initial
screen for active CHB. This is potentially a rational approach,
as therapy is only indicated for patients with both elevated ALT
and HBV DNA
5,19,20. However, liver function tests have limita-
tions because patients with advanced liver disease (for exam-
ple, fibrosis) may have normal liver function and therefore may
not receive appropriate treatment if HBV DNA levels are not
monitored in addition to ALT.
Treatment in the Midwest was shown to be a negative
predictor of HBV DNA monitoring. However, rates of monitor-
ing for both ALT and HBV DNA were found to be similar in this
patient population, suggesting that the rate of HBV DNA
monitoring is more limited than ALT monitoring (as most
patients who receive HBV DNA monitoring also receive ALT
monitoring). Low rates of monitoring in the Midwest may
reflect the distribution of CHB screening programs in the US;
a recent survey of community-based hepatitis screening
programs in the US identified few or no programs in the
Midwest, the American Southeast and the Southwest outside
of California and the Houston area
29.
The study results demonstrate a poor level of adherence to
guideline-recommended laboratory monitoring of CHB in
commercially insured patients, particularly monitoring of
HBV DNA. Since HBV DNA testing is a strong predictor of
treatment initiation, it is likely that the low rates of monitoring
may lead to delays in appropriate medical treatment of CHB.
Results of delaying treatment may include cirrhosis, liver
failure, and HCC, all of which may not become apparent until
late in the course of the disease
1,3,4.
Although this study provides interesting data, there are a
number of limitations that should be considered. Firstly, this is
a retrospective study using health insurance claims data. No
information was available regarding the ethnic, socioeconomic,
or educational distribution of the population and reasons for
monitoring or not monitoring. Secondly, the results of this
study may not be generally applicable to populations that are
not commercially insured; CHB patients covered under public
programs, such as Medicaid and Medicare, are not represented
in this dataset, nor are CHB patients who are undocumented
resident immigrants. It will be beneficial to include these
populations in future CHB monitoring studies in order to gain
a fuller picture of monitoring prevalence across different
patient groups.
This study demonstrated that, in a commercially insured
population of CHB patients, rates of guideline-recommended
laboratory monitoring were low and varied according to the
specific test. Improving monitoring rates may increase the
rates of medically appropriate treatment of CHB, preventing
delays in treatment initiation and, therefore, complications of
the disease.
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